

Medicines and Healthcare products Regulatory Agency

CERTIFICATE NUMBER : UK MIA(IMP) 14523 Insp GMP/IMP 14523/23497-0006[I]

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER(1),(2)

Part 1

Issued following an inspection in accordance with :

Part 6 of The Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004/1031)

The competent authority of United Kingdom confirms the following :

The Manufacturer : RAYNE CELL THERAPY SUITE (RCTS), THE RAYNE INSTITUTE, KING'S COLLEGE HOSPITAL & KING'S COLLEGE LONDON

Site address : RAYNE CELL THERAPY SUITE (RCTS), THE RAYNE INSTITUTE, KING'S COLLEGE HOSPITAL & KING'S COLLEGE LONDON, DEPARTMENT OF HAEMATOLOGICAL AND EXPERIMENTAL MEDICINE, THE RAYNE INSTITUTE, 123 COLDHARBOUR LANE, LONDON, SE5 9NU, UNITED KINGDOM

Has been inspected under the national inspection programme in connection with manufacturing authorisation no. UK MIA(IMP) 14523 in accordance with Part 6 of The Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004/1031)

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 13/07/2021 , it is considered that it complies with

- The principles and guidelines of Good Manufacturing Practice laid down in Regulation B17 of the Human Medicines Regulations 2012 (as amended)

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in MHRA-GMDP. If it does not appear, please contact the issuing authority.

- (1) Guidance on the interpretation of this template can be found in the Help menu of MHRA-GMDP database.
- (2) These requirements fulfil the GMP recommendations of WHO.

Part 2

Human Investigational Medicinal Products

1. MANUFACTURING OPERATIONS

[1.1] Sterile Investigational Medicinal Products

[1.1.1] Aseptically prepared (processing operations for the following dosage forms)

[1.1.1.4] Small volume liquids

[1.1.3] Batch certification

[1.3] Biological investigational medicinal products

[1.3.1] Biological medicinal products

[1.3.1.1] Blood products

[1.3.1.2] Immunological products

[1.3.1.3] Cell therapy products

[1.3.1.4] Gene therapy products

[1.3.1.5] Biotechnology products

[1.3.1.6] Human or animal extracted products

[1.3.2] Batch certification

[1.3.2.1] Blood products

[1.3.2.2] Immunological products

[1.3.2.3] Cell therapy products

[1.3.2.4] Gene therapy products

[1.3.2.5] Biotechnology products

[1.3.2.6] Human or animal extracted products

[1.4] Other products or manufacturing activity

[1.4.2] Sterilisation of active substances/excipients/finished products:

[1.4.2.1] Filtration

[1.5] Packaging

[1.5.2] Secondary packaging

[1.6] Quality control testing

[1.6.2] Microbiological: non-sterility

[1.6.3] Chemical/Physical

[1.6.4] Biological

2. IMPORTATION OF MEDICINAL PRODUCTS

[2.2] Batch certification of imported medicinal products

[2.2.1] Sterile Products

[2.2.1.1] Aseptically prepared

[2.2.3] Biological medicinal products

[2.2.3.1] Blood products

[2.2.3.2] Immunological products

[2.2.3.3] Cell therapy products

[2.2.3.4] Gene therapy products

[2.2.3.5] Biotechnology products

[2.2.3.6] Human or animal extracted products

[2.2.3.8] Other biological medicinal products

Tissue Engineered Products

[2.3] Other Importation Activities

[2.3.2] Importation of Intermediate which undergoes further processing

[2.3.4] Other

Importation of Intermediate which undergoes further processing

Any restrictions related to the scope of this certificate:

Building	Room Line/equipment	QC Testing	Products
No complex, blinded or randomised packaging activities are undertaken at this site.			Biotechnology products. Including cell therapy, immunological, gene therapy, blood products and autologous ATMP treatments.

20/09/2021 Name and signature of the authorised person of the Competent Authority of United Kingdom
Confidential
Medicines and Healthcare products Regulatory Agency
Tel : Confidential